Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (Q120492056)
(Redirected from Q120493784)
Scientific article published on 2 Dec 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia |
Scientific article published on 2 Dec 2016 |
Statements
2 references
10 July 2023
Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (English)
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
2 references
10 July 2023
Carolyn J Owen
2 references
10 July 2023
Helen McCarthy
2 references
10 July 2023
Jianyong Li
2 references
10 July 2023
Identifiers
1 reference